Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'
- Categories:Company News
- Author:
- Origin:
- Time of issue:2025-01-07
- Views:0
(Summary description)
Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future".
On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise
The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang.
Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。
Funds - the 'first pot of gold' that leverages innovation leverage
In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes.
"China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one
The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies.
Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile.
Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr
Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'
(Summary description)
Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future".
On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise
The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang.
Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。
Funds - the 'first pot of gold' that leverages innovation leverage
In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes.
"China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one
The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies.
Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile.
Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr
- Categories:Company News
- Author:
- Origin:
- Time of issue:2025-01-07
- Views:0
Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future".
On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise
The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang.
Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。
Funds - the 'first pot of gold' that leverages innovation leverage
In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes.
"China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one
The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies.
Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile.
Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution from preclinical to commercial stages, forming a continuous development ladder formation. Several of these research and development projects have obtained clinical licenses in the United States, taking a solid step towards innovative drugs going global.
Talent - a Strong Engine for Accelerating Innovation Supply
Talents are the foundation for the survival, development, and growth of enterprises. After more than ten years of deep cultivation, Shengshi Taike has not only won the "Grand Slam of Science and Technology Projects" from the national to the local level, but also achieved the "Grand Slam of Talents" from the national to the local level, forming a coordinated development of talents and science and technology projects.
At the end of 2021, the park took the lead in launching a pilot program for the evaluation of professional titles in biopharmaceutical engineering in China, and for the first time, biopharmaceutical engineering has a place in the domestic professional title sequence. In the first batch of approved candidates, Shengshi Taike has a total of 16 people on the list, of which 12 have been awarded the senior professional title of Biomedical Engineering. As one of the chairman members of the Suzhou Biomedical Engineering Advanced Professional Technical Qualification Evaluation Committee, Yu Qiang also personally experienced the evaluation process. In his opinion, if enterprises can select and evaluate a group of high-level professional title talents from a practical perspective, establish connections with universities or institutes through them, and have a talent "bridge", schools and enterprises can jointly develop a training system suitable for industrial talents in the future, and jointly create the "strongest magnetic field" for attracting and gathering talents.
The park fully considers the demand for innovative and entrepreneurial talents, not only creating a superior industrial environment, but also continuously improving the livable living environment. Up to now, Shengshi Taike has gradually improved the construction of the entire industry chain talent team from research and development to industrialization, and maintained a relatively stable talent team. Shengde, Innovation, Pragmatism, and Prosperity "are the" Eight Character Proverbs "of Shengshi Taike - only by maintaining good quality, continuous innovation, an attitude of seeking truth, and the original intention of benefiting the world, can we face storms and achieve our goals.
Innovation has always been the main line pursued by Shengshi Taike's development. Yu Qiang believes that for startups to achieve sustainable and upward development, their soul is talent, and their source is innovation. Therefore, Shengshi Taike strives to give its under development products certain advantages compared to existing clinical treatments. If it is a product targeting the same target, it should achieve both high quality and differentiation. In 2012, our team developed the predecessor of sengliptin, but its technical indicators were only on par with similar imported products in the market. We came here for innovation, and without surpassing the market's research and development achievements, it is not a breakthrough, let alone the support of governments at all levels for the company.
So, we resolutely overturned our original research and development plan and started over again until the end of 2016. As a result, the better performing sengliptin was finally launched and submitted a clinical application to the National Medical Products Administration Sagliptin not only improves high blood sugar, but also is less likely to induce low blood sugar and weight gain. It has the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and is known as the "smart" hypoglycemic drug with half the work and half the dosage.
Industry - the "last mile" of connecting the innovation ecosystem. Adhere to the path of innovation and sharpen a sword in ten years.
In August 2022, the first domestically produced Teriflunomide tablets developed by Shengshi Taike were launched for sale, bringing new choices and drug supply guarantees for multiple sclerosis (MS) patients in China. This also means that the company has officially entered the stage of commercial development.
At the end of 2024, after nearly eight years of "long-distance running", sengliptin was approved for market launch. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has not only been continuously shortlisted for the national "12th Five Year Plan" and "13th Five Year Plan" "Major New Drug Creation" special projects, but also been exempted from Phase 2 clinical trials and directly entered Phase 3 clinical trials due to excellent data demonstrated in the first phase clinical trials of the best products in the market, pioneering the "exemption from two to three" clinical trials in this drug field.
Pharmaceutical development, especially the research and development of innovative drugs, is a long cycle and high investment process. From the laboratory to commercialization, Teriflunomide and Sengliptin have already completed the "last mile". Their emergence has connected Shengshi Taike's "innovation chain" and "innovation path", verified the effectiveness of the company's carefully built innovation platform, and means that it can continue to develop new drugs in the future.
At present, the company is actively preparing for the commercialization of sengliptin, continuously expanding the market and bringing high-quality products to a wider patient population. At the same time, Shengshi Tyco has also arranged many projects in the field of diabetes and cancer, and is committed to providing more high-quality treatment programs to meet the needs of patients, becoming a new benchmark in the industry.
In the past decade or so of starting a business in the park, I have felt that the biggest change in the development of the park's industry is that the biopharmaceutical industry has grown from scratch to become the leading force in domestic innovation. Not only has the scale increased from over a hundred at that time to over a thousand today, but it has also created a complete ecosystem covering entrepreneurs, high-end talents, research institutes, and venture capital institutions, forming an industrial cluster advantage of upstream and downstream aggregation and joint innovation. Looking back on that period of time, Yu Qiang said that "emotions are a kind of power", and the original intention that drove him to embark on this entrepreneurial path was to hope that domestic patients could use high-quality domestic good drugs and new drugs.
Starting from the park after 30 years, Shengshi Taike's path of innovation and entrepreneurship will also reach a new level. In the future, the company will adhere to innovation from the source to meet clinical needs, benefit global patients, and help the biopharmaceutical industry in the park become stronger and bigger.


Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch
Contact Us
Tel: +86-512-62956960(Recruitment)
+86-512-62956961(marketing)
E-mail:hr@cgenetech.com.cn
Copyright © 2022 CGeneTech (Suzhou, China) Co., Ltd. All rights reserved. 苏ICP备2022006552号-1 Powered by 300.cn SEO